Jeffrey Foy
Corporate Officer/Principal chez PEPGEN INC.
Postes actifs de Jeffrey Foy
Sociétés | Poste | Début | Fin |
---|---|---|---|
PEPGEN INC. | Corporate Officer/Principal | - | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Corporate Officer/Principal | - | - |
Historique de carrière de Jeffrey Foy
Anciens postes connus de Jeffrey Foy
Sociétés | Poste | Début | Fin |
---|---|---|---|
DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Formation de Jeffrey Foy
Northeastern University | Graduate Degree |
University of Vermont | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Corporate Officer/Principal | 3 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
PEPGEN INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
- Bourse
- Insiders
- Jeffrey Foy
- Expérience